STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRC
  4. [6-K] SciSparc Ltd. Current Report (Foreign Issuer)

SciSparc (Nasdaq: SPRC) targets agentic AI, advances quantum platform

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

SciSparc Ltd. announced that its board has decided to target the agentic artificial intelligence market and will establish a Scientific Advisory Board focused on AI and cybersecurity. The company is evaluating opportunities and holding discussions with several agentic AI companies.

Subsidiary NeuroThera Labs Inc. reported successful internal validation of a proprietary quantum sampling workflow for clinical trial data analysis, built on an S&P 500 company’s hybrid quantum-classical computing platform. The platform is being advanced through CliniQuantum, a quantum-focused initiative in which NeuroThera holds 54.01%.

Positive

  • None.

Negative

  • None.

Filing Explained

The filing’s stated structural effect is to incorporate its two attached press releases by reference into SciSparc’s listed F-3 and S-8 registration statements, making this disclosure part of those filings.

AI initiative announcement date July 27, 2026 Date SciSparc announced decision to target the agentic AI market
Quantum platform validation date July 29, 2026 Date NeuroThera reported validation of its quantum sampling workflow
CliniQuantum ownership 54.01% NeuroThera’s interest in CliniQuantum, which advances the quantum platform
agentic artificial intelligence technical
"decision to target the agentic artificial intelligence ("AI") market"
A type of artificial intelligence that can set goals, make decisions, and carry out multi-step actions across digital or physical systems with limited human direction—think of it as an autonomous employee that plans and executes tasks. Investors care because agentic AI can boost productivity and create new revenue streams by automating complex work, but it also introduces risks (unexpected behavior, higher development costs, and regulatory scrutiny) that can affect company value and future cash flows.
Scientific Advisory Board regulatory
"decided to establish a Scientific Advisory Board to focus on AI"
A scientific advisory board is a group of independent experts—often scientists, clinicians or technical specialists—who give a company guidance on its research, product development and regulatory strategy. For investors, their role is like an external quality check: credible experts can reduce technical risk, improve the chance of regulatory approval or successful products, and boost confidence that management’s science claims are realistic and well-directed.
hybrid quantum-classical computing technical
"an S&P 500 company platform for hybrid quantum-classical computing"
A computing approach that pairs small quantum processors with conventional (classical) computers so each handles the tasks it does best: the quantum side tackles extremely hard, specialized calculations while the classical side manages routine control, data handling and decision-making. Like a hybrid car that uses an electric motor for efficiency and a gas engine for range, this mix can speed up specific problems such as optimization, materials modeling or drug discovery, which may create new product advantages, cost savings or revenue opportunities that investors monitor for signs of technological edge or commercial potential.
Quantum Markov Chain Monte Carlo technical
"enabling the application of Quantum Markov Chain Monte Carlo techniques"
A quantum Markov chain Monte Carlo method is a family of algorithms that use quantum computing ideas to sample from complicated probability distributions by letting a system hop through states in a controlled, random-like way. Think of it as replacing a slow explorer walking through a rugged landscape with a faster, quantum-enabled guide that can visit representative spots more efficiently; for investors, that can matter because faster or more accurate sampling helps price complex securities, estimate risk, and run Bayesian models used in forecasting and decision systems.
clinical-stage pharmaceutical medical
"a clinical-stage pharmaceutical company focused on developing novel treatments"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What strategic move did SciSparc (SPRC) announce regarding the agentic AI market?
SciSparc’s board decided to target the agentic artificial intelligence market and create a Scientific Advisory Board focused on AI and cybersecurity. The company is evaluating opportunities and is in discussions with several companies active in the agentic AI field.

What is the purpose of SciSparc (SPRC)’s new Scientific Advisory Board?
The new Scientific Advisory Board will focus on artificial intelligence and cybersecurity. Its role is to support SciSparc’s strategic move into the agentic AI market by providing scientific and technical guidance as the company explores collaborations and technology opportunities.

What quantum computing milestone did NeuroThera Labs, linked to SciSparc (SPRC), report?
NeuroThera Labs completed internal validation of a proprietary quantum sampling workflow for clinical trial data analysis. The workflow runs on a hybrid quantum-classical platform provided by an S&P 500 company, supporting advanced analytics on large-scale clinical and biomedical datasets.

How does NeuroThera’s quantum platform work according to SciSparc (SPRC)’s disclosure?
The platform converts continuous probability distributions into quantum-operable energy landscapes, enabling use of Quantum Markov Chain Monte Carlo (QMCMC) techniques. Quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the original target probability distribution in a hybrid architecture.

What is CliniQuantum and SciSparc (SPRC)’s connection through NeuroThera?
CliniQuantum is a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics. It is advancing NeuroThera’s quantum platform, and NeuroThera holds a 54.01% interest in CliniQuantum, giving SciSparc indirect exposure through its majority ownership of NeuroThera.

What is SciSparc (SPRC)’s core business outside of AI and quantum initiatives?
SciSparc, through majority-owned NeuroThera, focuses on clinical-stage cannabinoid pharmaceuticals, including programs SCI-110 and SCI-210 for Tourette syndrome, Alzheimer’s disease agitation, autism spectrum disorder, and status epilepticus. It also controls a business selling hemp seed oil-based products on Amazon.com.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026 (Report No. 2)

 

Commission File Number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

CONTENTS

 

On July 27, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.” On July 29, 2026, the Company issued a press release titled “SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company.” Copies of these press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report of Foreign Private Issuer on Form 6-K (this “Report”) and is incorporated by reference herein.

 

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release issued by SciSparc Ltd. titled “SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.”
99.2   Press release issued by SciSparc Ltd. titled “SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company.”

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SCISPARC LTD.
     
  By: /s/ Oz Adler
  Name:  Oz Adler
  Title: Chief Executive Officer and Chief Financial Officer

 

Date: July 29, 2026

 

3

 

Exhibit 99.1

 

 

 

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

 

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence (“AI”) market.

 

As part of this initiative, the Company has decided to establish a Scientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field.

 

About SciSparc Ltd. (Nasdaq: SPRC):

 

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

 

Forward-Looking Statements:

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the opportunities available to it in the agentic AI market. However, the Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by the formation of the Scientific Advisory Board. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

 

Exhibit 99.2

 

 

 

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

  

TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the “Platform”).

 

The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum-classical computing. The validation supports a key component of the Platform’s computational architecture and is expected to further expand the Platform’s capabilities for addressing complex analytical challenges involving large-scale clinical and biomedical datasets.

 

Many real-world challenges in healthcare, life sciences, drug development and advanced analytics are naturally represented as continuous probability distributions.  The Platform’s proprietary methodology converts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov Chain Monte Carlo (“QMCMC”) techniques while preserving the statistical characteristics of the original data.

 

By using the Platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous datasets to be explored through quantum-generated proposals while maintaining established statistical guarantees.

 

The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. NeuroThera believes efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life sciences.

 

The Platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%.

 

About SciSparc Ltd. (Nasdaq: SPRC):

 

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

 

 

About NeuroThera Labs Inc.

 

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

 

Forward-Looking Statements:

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the anticipated capabilities, performance, scalability and utility of NeuroThera’s quantum platform and of the validated quantum sampling workflow; the belief that efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life sciences; the expectation that quantum computing technologies will continue to evolve in a manner that supports increasingly sophisticated analytical capabilities; the applicability of the platform to clinical, biomedical and drug development datasets; the continued development of the platform through CliniQuantum; NeuroThera’s ownership interest in CliniQuantum; and NeuroThera’s business objectives, plans and strategy generally.. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

 

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

  

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases